GlaxoSmithKline has reached a $49 million settlement agreement with a class of direct purchasers who accused the drug maker of bringing “sham” patent litigation against manufacturers of generic versions of its popular antidepressant Wellbutrin SR in an attempt to prolong its monopoly on the market.

The plaintiffs filed a motion for final approval of the settlement on Friday, about four-and-a-half months after the parties reached an agreement during mediation.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]